Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Receivables (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Receivables data on record, last reported at $147.3 million in Q3 2025.

  • For Q3 2025, Receivables rose 5.19% year-over-year to $147.3 million; the TTM value through Sep 2025 reached $147.3 million, up 5.19%, while the annual FY2024 figure was $136.3 million, 18.57% up from the prior year.
  • Receivables reached $147.3 million in Q3 2025 per AMPH's latest filing, up from $133.5 million in the prior quarter.
  • Across five years, Receivables topped out at $147.3 million in Q3 2025 and bottomed at $67.9 million in Q2 2021.
  • Average Receivables over 5 years is $107.2 million, with a median of $104.7 million recorded in 2023.
  • Peak YoY movement for Receivables: fell 6.12% in 2022, then skyrocketed 53.93% in 2023.
  • A 5-year view of Receivables shows it stood at $78.8 million in 2021, then grew by 12.69% to $88.8 million in 2022, then rose by 29.43% to $114.9 million in 2023, then rose by 18.57% to $136.3 million in 2024, then rose by 8.09% to $147.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $147.3 million in Q3 2025, $133.5 million in Q2 2025, and $144.8 million in Q1 2025.